Tech Company Financing Transactions
Regado Biosciences Funding Round
Private investors participated in a $11.6 million Series D capital raise for Regado Biosciences. The round was recorded on 7/5/2011.
Transaction Overview
Company Name
Announced On
7/5/2011
Transaction Type
Venture Equity
Amount
$11,599,999
Round
Series D
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. Series D preferred stock. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
701 Gateway Blvd. 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Regado (NASDAQ: RGDO) is a spin-out of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug-antidote pairs against any target accessible to the bloodstream.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laurent Fischer
Chief Financial Officer
Christopher Peetz
Chief Medical Officer
Eric Lefebvre
Chief Operating Officer
Helen Jenkins
Browse more venture capital transactions:
Prev: 7/5/2011: PayScale venture capital transaction
Next: 7/5/2011: LightSquared venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs